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Background: Although hypercholesterolemia is considered a cardiovascular risk factor, in isolation it is not
necessarily sufficient cause for a cardiovascular event. To improve event prediction, cardiovascular risk calculators
have been developed; the REGICOR calculator has been validated for use in our population. The objective of this
project is to develop an intervention with general practitioners (GPs) and evaluate its impact on prescription
adequacy of cholesterol-lowering drugs in primary prevention of cardiovascular disease and in controlling the costs
associated with this disease.
Methods: This nonblinded, cluster-randomized clinical trial analyzes data from primary care electronic medical records
(ECAP) and other databases. Inclusion criteria are patients aged 35 to 74 years with no known cardiovascular disease
and a new prescription for cholesterol-lowering drugs during the 2-year study period. Dependent variables include the
following: RETIRA, defined as new cholesterol-lowering drugs initiated during the year preceding the intervention,
considered inadequate, and withdrawn during the study period; EVITA, defined as new cholesterol-lowering
drugs initiated during the study period and considered inadequate; COST, defined as the total cost of inadequate
new treatments prescribed; and REGISTER, defined as the recording of cardiovascular risk factors. Independent variables
include the GP’s quality-of-care indicators and randomly assigned study group (intervention vs control), patient
demographics, and clinical variables. Aggregated descriptive analysis will be done at the GP level and multilevel
analysis will be performed to estimate the intervention effect, adjusted for individual and GP variables.
Discussion: The study objective is to generate evidence about the effectiveness of implementing feedback
information programs directed to GPs in the context of Primary Care. The goal is to improve the prescription
adequacy of lipid-lowering therapies for primary prevention.
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Primary care medicine has included a focus on preven-
tion for decades, but the possible side effects of prevent-
ive treatments were unknown or underemphasized.
More recently, these possible risks have taken on
greater importance in clinical practice [1,2], making
the population aware of the potential harms associated
with prevention efforts.
Hypercholesterolemia as a risk factor
The treatment of hypercholesterolemia, a risk factor for
cardiovascular disease, is a well-established preventive
action; its association with increased incidence of ische-
mic heart disease has been described together with
smoking, hypertension, and diabetes as cardiovascular
risk factors (CVRF). In the Seven Country Study [3],
total cholesterol of 200 mg/dl was associated with a car-
diovascular mortality rate of 15% in the northern coun-
tries of Europe, compared to 3% in the south (results
adjusted for age and other CVRF). This implies that, in
isolation, the role of hypercholesterolemia in the incidence
of cardiovascular events is neither essential (cardiovascu-
lar events occur in the absence of hypercholesterolemia)
nor sufficient (most patients with high cholesterol do not
have cardiovascular events) [4].
For this reason, the various models of cardiovascular
risk calculation incorporate the presence of other risk
factors and are not based exclusively on hypercholester-
olemia [5]. Therefore, the calculation of cardiovascular
risk is a tool for classifying patients according to their
risk and contributes to decisions on hypercholesterol-
emia treatment, focusing on decreasing the incidence
and mortality rates associated with cardiovascular dis-
ease rather than the potential benefits of intermediate
outcomes such as lower levels of low-density lipopro-
teins (LDL) and total cholesterol [6].
Repercussions of inadequate use of cholesterol-lowering
drugs in primary prevention
Pharmacological treatment of hypercholesterolemia is
indicated in two different groups of patients: those with
and without cardiovascular disease (primary and second-
ary prevention, respectively). At present, there is no
question about the indications and benefits of this ther-
apy in secondary prevention [7]. Achieving cholesterol
reduction objectives is usually included in evaluations of
clinical management. In our context, indicators of LDL
cholesterol control in patients with cerebrovascular dis-
ease and ischemic heart disease are available dating back
to 2007, when the electronic medical records system was
implemented. Data include monthly monitoring and
feedback and asynchronous reminders to all primary
care centers (PCC) within the Catalan Institute of Health
(ICS: Institut Català de Salut) system. Since January2009, secondary prevention results (adequate LDL con-
trol) have improved 21.87% for cerebrovascular disease
and 15.97% for ischemic heart disease.
In primary prevention, on the other hand, drug ther-
apies continue to be debated for two main reasons. First,
no benefit has been demonstrated in women, elderly,
and low-risk patients [8]. Second, differences between
the criteria established in various guidelines and consen-
sus documents result in a variable clinical impact with
respect to the number of patients for whom treatment is
indicated [9]. In contrast to secondary prevention, clin-
ical assessments in primary prevention do not include a
monitoring of treatment adequacy, despite the possible
“medicalizing” impact associated with assigning a label
and treatment and the potential consequences for the
patient’s quality of life.
It is also unclear whether primary prevention drains
resources that could be directed to other clinical areas.
The increased prescription of cholesterol-lowering drugs
in national health systems [10] has had a major impact
on pharmaceutical expenditures; the greatest cost is for
statins, as a group. Few studies have analyzed the distribu-
tion of this increased cost [11-13], but inadequate pre-
scription of cholesterol-lowering drugs has been reported
both as underutilization in high-risk patients and overuti-
lization in low-risk patients [14].
Improvement in prescription adequacy requires that
we address multiple factors, because this does not de-
pend exclusively on improved adherence to clinical rec-
ommendations [15]. Of the factors to be considered, we
would highlight two: the general practitioner (GP) faces
challenges in interpreting results and recommendations
from trials with methodological biases and marginal
population-level benefit [8], and the influence of the
pharmaceutical and food products industries is evident
in the presentation of clinical trial results that empha-
sizes relative risk [16], with messages about the need to
measure cholesterol levels and lower them with drug
therapies that can prevent premature death in the
healthy general population [17,18].
Interventions to improve prescription adequacy
Several different types of intervention studies have been
conducted in an effort to improve prescription adequacy
in clinical practice. These can be grouped into three
major types of intervention: 1) feedback or audits [19],
in which information about clinical practice is a poster-
iori; 2) alerts or reminders [20], which suggest an action
such as preventive care at the time of the patient visit or
a priori; and 3) clinical decision support systems (CDSS)
[21], which are more complex systems that guide practi-
tioners and provide recommendations on clinical deci-
sions to be made, based on information added to the
clinical record.
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signed to improve clinical practice, Cochrane concluded
that feedback leads to slight or moderate improvement
[20]. A recent clinical trial, better adapted to the characteris-
tics of our environment [22], demonstrates major variations
in carrying out preventive activities such as vaccinations,
comparing usual practice with message alerts and alerts plus
feedback. The progressive computerization of our primary
care system creates a unique opportunity to develop inter-
ventions: the electronic medical records system is fully im-
plemented in all health centers administered by the ICS and
information systems are available that support the use of
quality indicators and provide feedback to health care profes-
sionals –with or without economic incentives. Although
these may have a moderate impact, their low cost and the
possibility of adapting them to provide personalized informa-
tion, whether in real time or asynchronously, offer enormous
intervention potential.
For all these reasons, given the concerns generated
by current statins prescription as a primary preven-
tion strategy and the opportunity offered by informa-
tion systems based on electronic medical records, this
clinical trial is designed to evaluate the effectiveness
of an intervention intended to improve the pharma-
cological approach to hypercholesterolemia in pri-
mary prevention.
Research hypotheses
Inadequate prescription of cholesterol-lowering drugs in
patients with no history of cardiovascular disease may
have negative repercussions for the patient as well as for
the health care system.
Implementation of an intervention designed for GPs in
primary care and based on informational feedback con-
cerning the adequacy of prescribed cholesterol-lowering
drugs could strengthen their competency, their adher-
ence to clinical practice guidelines (CPG), and overall ef-
forts to contain health care costs.
Objectives
Primary objective
To evaluate the effectiveness of an intervention directed to
primary care GPs, based on providing informational feed-
back about the adequacy of using cholesterol-lowering
drugs in primary prevention, and designed to improve pre-
scription practices according to the recommendations in
clinical practice guidelines and to reduce health care costs,
compared to current practice.
Secondary objectives
1. To describe demographic and clinical characteristics
of patients receiving new prescriptions for
cholesterol-lowering drugs.2. To determine the degree of adequate prescription of
cholesterol-lowering drugs in patients treated for
primary prevention (i.e., without previous history of
cardiovascular disease).
3. To identify the factors associated with adequate
prescription of cholesterol-lowering drugs in primary
prevention.
4. To analyze the degree to which cardiovascular risk is
recorded in electronic medical records after the
intervention.
5. To determine the economic impact of the
cholesterol-lowering drugs prescribed for primary
prevention during the study period.
Method
Study design
The design is a multicenter, controlled, cluster-randomized,
nonblinded clinical trial to evaluate the effectiveness of an
intervention related to the prescription of cholesterol-
lowering drugs in primary prevention, compared to usual
clinical practice.
Setting
All individuals attended in 283 primary care center
(PCC) managed by the ICS, which cover a population of
5.8 million urban, semi-urban, and rural residents of
Catalonia.
Study population
Twelve PCC are excluded because their current partici-
pation in a different intervention could invalidate the re-
sults of this study. The research team will identify all
patients aged 35 to 74 years who received a new prescrip-
tion for cholesterol-lowering drugs from the remaining
271 PCC during the study period (October 1, 2011-
September 30, 2013), as recorded in the electronic medical
records system, known as ECAP. Exclusion criteria are any
history of cardiovascular disease (ischemic heart disease,
cerebrovascular accident, or peripheral artery disease) re-
corded in ECAP and patients for whom pharmacy records
showed receipt of a cholesterol-lowering prescription drug
during the 12 months preceding their inclusion in the study.
Randomization
The unit of randomization is the PCC. This avoids a
possible contamination effect if different health profes-
sionals from the same PCC were randomized to different
study groups. Cluster randomization will be done by
random-sized blocs of PCCs (i.e., 2,4,6,8,10), stratified in
quartiles by a synthetic PCC quality care indicator,
“EQA” [23]. This method will ensure that each study
group has the same number of PCCs and GPs and that
there is a balanced distribution of the EQA covariate be-
tween the two groups [24,25].
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Due to the nature of the intervention, GPs in the inter-
vention group cannot be blinded to their group assign-
ment. However, the researcher responsible for data
analysis will be blinded to study group assignments.
Intervention design
Based on the list of patients with inclusion and exclusion
criteria, the research team will analyze the adequacy of
new prescriptions for cholesterol-lowering drugs, based
on the recommendations contained in ICS clinical prac-
tice guidelines on cholesterol and coronary risk [26]. The
flow chart for this analysis is included as Additional file 1.
All GPs assigned to the intervention group will receive
informational feedback about the adequacy of cholesterol-
lowering drugs prescribed for their patients. Feedback is
provided as part of the ECAP system capabilities. The
preparation and dissemination of intervention-related
feedback will be monthly, beginning in the second year of
the study (October 1, 2012-September 30, 2013). This in-
formation, available to the GPs at their convenience, will
be presented in two distinct and complementary formats
and updated throughout 12 consecutive months:
1. Asynchronous information (patient not present)
a) Quantitative information about the percentage
of the GP’s assigned patients who have started
primary cardiovascular prevention therapy with
cholesterol-lowering drugs and that is considered
correctly indicated according to the criteria
established in the corresponding ICS clinical
practice guidelines [26].
b) List of names of patients who have started
primary cardiovascular prevention therapy with
cholesterol-lowering drugs but do not meet the
guidelines criteria.
2. Real-time information (patient present when
information is presented to GP).
3. In each GP’s daily schedule, an alert symbol will
indicate appointments with patients who have
started statins therapy for primary cardiovascular
prevention without meeting the established indications
criteria. In addition, a message will be included in the
ECAP system of clinical advisories. This screen, used
during the patient visit, shows all active clinical
advisories and alerts for that specific patient. This
may include EQA information, medication safety
considerations, notice of availability of test results, etc.
The GPs assigned to the control group will not receive
the project’s ECAP feedback. The study algorithm is
diagrammed in Additional file 2.
The research team will carry out the analysis of pre-
scription adequacy. Implementation of ECAP feedbackwill be the responsibility of the SISAP team (Sistema de
Informació dels Serveis d’Atenció Primària), the ICS unit
that provides clinical practice information to ICS pri-
mary care professionals and administrators [26].
A pilot study was conducted with GPs selected from
two primary care centers. This study ensured that data
extraction and information alerts worked correctly. Data
for these GPs will be excluded from the final results.
Outcomes
New treatment with cholesterol-lowering drugs is de-
fined as a prescription given to a patient who has not
collected any such prescription from a pharmacy during
the 12 months preceding study inclusion, according to
national health system records.
Primary prevention is considered the absence of car-
diovascular disease (ischemic heart disease, cerebrovas-
cular accident, peripheral artery disease).
The ICS clinical practice guidelines on cholesterol and
coronary risk are applied to determine prescription ad-
equacy when cholesterol-lowering drugs are prescribed
for primary prevention [26]. To operationalize the algo-
rithm, adequate treatment is defined as meeting one or
both of the following criteria:
A. At least 10% cardiovascular risk, according to
REGICOR 10-year risk calculated within 12 months
of treatment initiation. The REGICOR risk function
has been calibrated and adapted to local incidence
and distribution of risk factors in Catalonia [27]. It
stratifies cardiovascular risk into 4 classifications:
low (<5%), moderate (5%–9.9%), high (10%-14.9%),
and very high (>15%). The ICS clinical practice
guidelines recommend the use of REGICOR tables
to calculate coronary risk and consider individuals
with at least 10% risk of a 10-year coronary event to
be candidates for more intensive interventions, which
may include cholesterol-lowering drugs. Additional
file 3 contains the REGICOR risk tables, adapted from
the Framingham risk calculation.
B. At least 240 mg/dl LDL cholesterol recorded during
the 12 months preceding treatment initiation.
Primary outcomes
The primary study variable is improved prescription
adequacy in the use of cholesterol-lowering drugs for
primary prevention of cardiovascular disease according
to the recommendations of ICS clinical practice guide-
lines, comparing the intervention group to usual clin-
ical practice.
Two dependent variables will be analyzed to address
the primary objective:
RETIRA, defined as new cholesterol-lowering drugs initi-
ated during the year preceding the intervention, considered
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feedback information. This variable is directly affected by
the intervention because patient records included in the
calculation of this variable will be precisely those that trig-
gered the intervention feedback.
EVITA, defined as new cholesterol-lowering drugs ini-
tiated during the 12 months follow-up period and con-
sidered inadequate.
Improved prescription adequacy is defined as an in-
crease in the RETIRA variable and decrease in the
EVITA variable.
Secondary outcomes
– To assess the recording of cardiovascular risk in
electronic medical records, the REGISTER variable
will be calculated: number of patients with no
history of cardiovascular disease (primary
prevention) treated with statins without having any
record of a cardiovascular risk calculation.
– To assess the economic impact of prescriptions, the
COST variable will be calculated: the total cost of all
prescriptions for new cholesterol-lowering drugs in
primary prevention reimbursed by the national
health system that are considered inadequate during
the study period.
The intervention is designed to produce an increase in
the REGISTER variable and a decrease in the COST
variable.
Other variables
The primary independent variable is the GP’s assigned
study group (intervention or control group).
Patient variables: age, sex, new statin prescription picked
up from a pharmacy, cardiovascular risk (calculated using
the REGICOR formula and recorded in ECAP), choles-
terol (total, LDL and HDL), systolic and diastolic blood
pressure, smoking habit, treatment group from the catalog
of statins (Anatomic, Therapeutic, Chemical [ATC] code),
and diagnosed cardiovascular disease, diabetes mellitus, or
hypertension, according to International Classification of
Diseases (ICD-10 codes), listed below:
– Myocardial infarction: I21 and subtypes, I22 and
subtypes, I23 and subtypes, I25.2
– Ictus: I60 and subtypes, I62 and subtypes, I63 and
subtypes I64
– Peripheral artery disease: I73, I73.8, I73.9
– Tobacco use: F17 and subtypes F17.1 – F17.9
– Diabetes Mellitus: E11 and subtypes, E12 and
subtypes, E13 and subtypes, E14 and subtypes
– Arterial hypertension: I10, I15, I15.1, I15.2, I15.8,
I15.9.General practitioner variables
– EQR: SIDIAP has developed this synthetic index
showing the quality standard of each GP’s data
recording in the ECAP system.
– EQPF: This ICS synthetic indicator reflects the
quality (adequacy) of drug prescription for each
GP.
– EQA: This ICS synthetic indicator reflects the
overall quality of care provided by each GP, based
on established ICS standards.
– Use of the intervention: SISAP provides a monthly
summary of the number of time each GP accesses
the information provided in ECAP.
– Teaching responsibilities: This variable reflects
whether or not the GP works with a resident
physician.
The patient and GP variables analyzed also allow a de-
scription of the use of cholesterol-lowering drugs for pri-
mary prevention and the associated factors that are
relevant to the secondary objectives.
Data collection and follow-up
Most of the study variables will be obtained from the
population-based SIDIAP database (Sistema d’Informació
pel Desenvolupament d’Investigació en Atenció Primària)
[28], which is similar to other European databases such
as Clinical Practice Research Database (CPRD), Quality
database for ethical research (QRESEARCH), Out-Patient
Pharmacy Database (PHARMO), or The Health Improve-
ment Network (THIN). The SIDIAP database contains
anonymized data from 5.8 million individual patients in
the ICS electronic medical records system and from com-
plementary sources that provide valid, reliable information
for research about primary care. This database is represen-
tative of Catalonia as a whole (www.sidiap.org) and in-
cludes the following information:
1. ECAP data on sociodemographic variables, primary
care visits, diagnoses (ICD-10 codes), clinical
variables, prescriptions, immunizations, and
background. ECAP implementation began in 1998
and has been used in routine practice since 2005 in
all PCC managed by ICS.
2. Pharmacy records:
Pharmacy records: Information on medication
dispensed in community pharmacies since 2005,
including the associated cost.
3. Laboratory tests: Results are available for all tests
since 2006.
Finally, to complete the identification of patients with
a history of cardiovascular disease, hospital discharge
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(Minimum Basic DataSet).
Sample size
The preliminary study conducted by the research team
showed the availability of a sample size of approximately
60,000 new statin treatments prescribed each year. As-
suming 90% strength, 5% alpha error, a 1:1 ratio of con-
trol to intervention participants, corrected by the cluster
design and assuming 10% loss to follow-up, our study
could detect a difference of 1% (according to the medical
criteria applied by the experts on the research team) at a
90% confidence interval. Even with this strength level, a
clinically relevant difference of 10% can be established.
Statistical analysis
Initially, descriptive analysis will be completed for all
study variables: mean (standard deviation) for continu-
ous variables with a normal distribution, median (inter-
quartile ranges) in the case of non-normal distribution
and the frequency (percentage) of categorical variables.
Differences between the intervention and control groups
will be assessed using the χ2 or Fisher exact test for categor-
ical variables and Student t for continuous variables with
normal distribution, or nonparametric Mann–Whitney U
test, as appropriate. Differences between means, medians, or
ratios at the beginning and end of the two-year follow-up
period (pre- and post-intervention) will be compared using
the McNemar test, Student t for paired tests, or Wilcoxon
test, as appropriate.
The percent change with respect to baseline value is
used as a measure of the pre- and post-intervention
change in categorical variables, calculated as the final
percentage minus the initial percentage × 100.
The intervention effect after one year of follow-up will
be evaluated using the decrease in the EVITA variable
and increase in the RETIRA variable. To assess the effect
of the intervention model, a multilevel logistic regression
analysis will be performed, considering intervention vs
control group as the independent variable. The analysis
will be adjusted for potential predictive independent var-
iables and, for those considered clinically relevant, for
baseline values.
To determine the economic impact of new prescrip-
tions of cholesterol-lowering drugs in primary preven-
tion prescribed during the study period, a descriptive
analysis of costs and resource use will be completed for
each study group and the groups will be compared (dis-
count rate: 3%). The incremental cost-effectiveness ratio
will be calculated as the difference between the cost
average for the 2 study groups, divided by the difference
between the effects for both groups. Acceptance curves
will be calculated to determine the cost-effectiveness of
the intervention compared to usual practice.Significance will be established at the 5% level. All ana-
lysis will be done using Stata/SE, version 10.1 (StataCorp).
Research ethics
The study will follow the national and international
norms defined in the Declarations of Helsinki and
Tokyo, as well as the recommendations of the Clinical
Research Ethics Committee (CEIC) of our research insti-
tute, the Institut Universitari d’Investigació en Atenció
Primària (IDIAP) Jordi Gol. Confidentiality of personal
data is guaranteed for all participants in accordance with
Spanish Law (LOPD: Ley Orgánica de Protección de
Datos de Carácter Personal 15/1999, 13 December).
The data included in the SIDIAP database are anon-
ymized and identified only by an internal code, created
when the record is created; personal identification of pa-
tients by the research team is impossible. All PCC will
be informed about the study outcomes.
To further guarantee confidentiality, SIDIAP has a
protocol for linking records with external databases such
as the CMBD-AH, and information provided by SISAP
does not contain patient-identifying data. The procedure
used consistently by SISAP is that anonymized codes are
assigned, which the ECAP system decodes when infor-
mation is provided to professionals responsible for that
patient’s care.
Discussion
The results of this trial will provide new evidence of the
effectiveness of an intervention based on clinical advice
and feedback to primary care professionals via electronic
medical records information. Extensive computerization
of PCC records allows the creation of mechanisms and
instruments to help the professional improve his or her
approach to particular health problems and adherence
to current clinical practice guidelines.
There are major problems with pharmacological treat-
ment for the primary prevention of hypercholesterolemia,
including a high percentage of patients being treated in-
appropriately under established guidelines. It is a priority
to address these problems within PCCs, in order to avoid
negative consequences for patients as well as for the
health care system.
This trial will be conducted in a broad population of
more than 5 million patients, which results in sufficient
strength to obtain significant results. In addition, evaluation
of the intervention will be based on an information system
that has been widely studied and validated, the SIDIAP.
In any case, the study has several limitations, which we
have attempted to address. One assumes that all databases
(such as SIDIAP) have a certain level of underreporting
on variables of interest, although this should not differ be-
tween the two randomized study groups. In our case, data
recording in the electronic medical records should be
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ity indicators that are incentivized by the ICS payment
systems. In addition, one of the study variables, EQR, is
the level of professional quality, which allows a sub-
analysis of the quality of the services provided. To avoid
the loss of recorded diagnoses, any diagnosis of cardiovas-
cular disease recorded in the electronic medical record
will be complemented with hospital discharge diagnostic
data. With respect to the treatment variables, the records
are reliable because the data are taken from the pharma-
cies’ invoicing system for national health system reim-
bursement for the prescriptions they filled for patients.
The fact that the groups are not blinded is a limitation
of the intervention, and the possibility of contamination
between groups could limit the study conclusions. None-
theless, we attempt to evaluate the effectiveness of an
intervention in a real-life context linked to normal clin-
ical practice, where this type of situation is quite fre-
quent. Randomization by PCC rather than by individual
GP reduces the probability of contamination between
the study groups.
In conclusion, this study contributes new knowledge
about interventions that can improve the prescription of
cholesterol-lowering drugs by following the recommenda-
tions in clinical practice guidelines, and can help to reduce
health care costs. We consider this study very valuable for
informing health care professionals about changes that
can be made, based on the information received in PCC.
The study provides an idea of usual clinical practice by
primary care professionals related to the adequacy of
cholesterol-lowering drug prescriptions for primary pre-
vention. At the same time, it allows us to evaluate possible
changes that could occur naturally after an intervention
related to the proper prescription of cholesterol-lowering
drugs. This study could have special relevance because of
the enormous potential offered by the low cost of the
intervention and the possibility of adapting the electronic
medical records system to provide personalized informa-
tion, whether in real time or asynchronously.
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Additional file 1: Catalan Institute of Health Clinical Guidelines for
Primary Prevention of Cardiovascular Disease [26].
Additional file 2: Study algorithm.
Additional file 3: Framingham-REGICOR adapted risk charts,
simplified into four risk categories based on event concentration
data and the 10-year risk cutoff values proposed by experts from
various autonomous communities in Spain.
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